Cytodyn’s Leronlimab Could Be an Answer to COVID-19

Although the news about CytoDyn (CYDY) saying it could probably adapt its leronlimab drug to battle COVID-19, is two weeks old, the media finally caught up with the story when news that a small sample of patients with COVID-19 have responded positively to the drug treatment.In this article we’ll look at the potential opportunity this offers patients and CytoDyn, and also the many other diseases and conditions leronlimab could be useful for.Leronlimab and COVID-19The primary use and benefit of leronlimab is for patients having respiratory complications from COVID-19. At this time it is believed the treatment strengthens the “immune response …read more

Source:: Yahoo Finance

      

Did you enjoy this article? Join our FREE Newsletter!
I agree to have my personal information transfered to MailChimp ( more information )
Join over 100,000 investors and business leaders worldwide. Get the latest actionable business and investing intelligence before the rest of the crowd.
We hate spam. Your email address will not be sold or shared with anyone else.